#Japan #Tokyo #Prolacta #JASMINE Trial #NEC Prevention

The JASMINE Trial: A New Dawn in Neonatal Nutrition

In a groundbreaking development for neonatal care, the JASMINE trial has provided compelling evidence supporting the use of Prolacta Bioscience's human milk-based fortifiers for premature infants. This landmark clinical trial, published in the Journal of Perinatology, highlights the successful resolution of a critical dilemma faced by neonatal clinicians in Japan: delivering essential nutrition to extremely premature infants while maintaining an exceptionally low rate of necrotizing enterocolitis (NEC).

Background of the Trial

Japan is recognized globally for its high survival rates of preterm infants, with 80% to 90% of those born at 22 to 24 weeks gestation surviving to discharge. However, the current standard practices in Japan often lead to delays in providing critical nutrition, which is vital for the growth and neurodevelopment of these fragile infants. The hesitancy to introduce cow milk-based fortifiers has contributed to inadequate nutritional intake.

The JASMINE trial conducted research across 11 neonatal intensive care units (NICUs) in Japan. It compared the outcomes of feeding infants Prolacta’s human milk-based fortifiers versus the standard approach that employs cow milk-based fortifiers, known to carry risks of NEC and other complications. The evidence gathered is set to change how clinicians approach neonatal nutrition in Japan and potentially amongst other countries.

Key Findings from the JASMINE Trial

The findings from the JASMINE trial were compelling. Infants who were fed with Prolacta's fortifiers showed significantly improved growth rates, specifically a weight gain of 14.30 grams per kilogram per day compared to 11.96 grams for those on the standard diet. These infants also reached full feeds earlier (20 days vs. 25.9 days) and required fewer days on antibiotics, underpinning a safety profile that aligns with Japan’s healthcare standards. This level of growth is crucial, as better weight gain is closely linked to positive long-term neurodevelopmental outcomes.

Lead author Dr. Katsumi Mizuno articulated the significance of these results, emphasizing that the introduction of human milk-based fortifiers would allow Japanese clinicians to help infants thrive without compromising their safety and wellness. The ideal scenario for neonatal care would involve ensuring that infants not only survive but also flourish through effective nutritional strategies.

The Importance of Human Milk Fat in Development

Human milk is a rich source of vital nutrients, including intact milk fat globules (MFGs), which are essential for the development of the infant brain. Prolacta's human milk-derived fat modular, Prolact CR®, played a pivotal role in the JASMINE protocol, with over 95% of infants in the human milk arm receiving this product. The significant presence of human milk oligosaccharides (HMOs) in Prolacta's fortifiers enhances their nutritional profile, potentially leading to better health outcomes than traditional cow milk-based products.

The JASMINE study demonstrated that infants fed an exclusive human milk diet (EHMD) exhibited better weight gain and length velocity, along with a marked reduction in antibiotic usage, indicating a robust response to the fortification approach.

Future Implications and Regulatory Changes

Following the robust findings from the trial, including a safety profile consistent with neonatal expectations, Japan's Ministry of Health, Labour, and Welfare granted Prolacta’s human milk-based fortifiers prescription drug status—the first of its kind. This decision not only strengthens the case for human milk-based nutrition globally but also paves the way for similar practices in other countries seeking to improve neonatal outcomes.

Moving forward, there is a growing body of evidence suggesting the connection between early human milk-based fortification and improved neurodevelopment in premature infants. Subsequent studies have shown that these infants are less likely to experience developmental delays and may achieve cognitive scores comparable to those of full-term infants.

Conclusion

The JASMINE trial marks a pivotal moment in neonatal care, demonstrating that evidence-based approaches can directly enhance both growth and safety for the most vulnerable patients. Prolacta's advancements in human milk-based fortifiers provide a powerful alternative to traditional nutrition practices, ultimately enabling healthcare providers to balance the critical need for rapid growth with the imperatives of safety and long-term developmental success. As the integration of these innovative solutions becomes standard practice, we can hope for a future where more premature infants not only survive but truly thrive.